Chosa Oncology (CHOSA) investor relations material

Executive summary

• Q1 2026 marked a strategically important period with continued focus on positioning Platin-DRP® as a key precision medicine tool in platinum-based chemotherapy, especially for lung cancer.

• Positive new survival data from the phase III SPLENDOUR study presented at ELCC 2026 reinforced Platin-DRP®'s clinical relevance in predicting overall survival in advanced NSCLC.

• A directed share issue of approximately 7.3 MSEK in January strengthened the financial base and enabled further development of Platin-DRP®.

• A new patent application was filed focusing on platinum response and synergies with immunotherapy, expanding the intellectual property position.

Financial highlights

• Net result after financial items for Q1 2026 was -1,867 TSEK, compared to -1,807 TSEK in Q1 2025.

• Earnings per share after dilution was -0.021 SEK (Q1 2025: -0.025 SEK).

• Liquidity at March 31, 2026, was 5,637 TSEK, up from 3,402 TSEK a year earlier.

• Equity increased to 21,673 TSEK (Q1 2025: 11,628 TSEK), with a total balance sheet of 23,812 TSEK (Q1 2025: 12,976 TSEK).

• Solid equity ratio of 91% at quarter-end (Q1 2025: 90%).

Outlook and guidance

• The company sees growing opportunities as platinum remains a cornerstone therapy in major cancer indications, increasingly combined with immunotherapy.

• There is a significant unmet clinical need for precision tools to guide platinum therapy, representing a strategic opportunity.

• The ambition is to validate Platin-DRP® not only in retrospective studies but also as a decision support in modern oncology.